Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.64 |
| ▸ | HTR1A | P08908 | 4/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | DRD2 | P14416 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.64 |
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | HTR2C | P28335 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15805952 | 0.85 | PIM1 (0.58) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL30349813 | 0.84 | CYP2D6 (0.70) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL21436140 | 0.84 | CYP2D6 (0.70) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL7066913 | 0.84 | CYP2D6 (0.70) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL14292498 | 0.83 | CYP2D6 (0.68) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL21977514 | 0.83 | CYP2D6 (0.68) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL14292497 | 0.83 | LMNA (0.72) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL14707115 | 0.83 | PIM1 (0.75) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL8053156 | 0.82 | CYP2D6 (0.71) | LMNACYP1A2HTR1ACYP2D6MAPT | |
| SCHEMBL29724166 | 0.82 | CYP2D6 (0.71) | LMNACYP1A2HTR1ACYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2744808-A2 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | Mount Sinai School of Medicine (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013025882-A2 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013025882-A2 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TFEB, FOXO3, FOXO1 | LMNA 4094/4885CYP1A2 2436/4885HTR1A 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.